A long-term, open-label study of the safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.012 ◽

2004 ◽

Vol 50 (3) ◽

pp. P2 ◽

Author(s):

Alan Menter ◽

Deborah Lew-Kaya ◽

Frederick Beddingfield ◽

Patricia S. Walker

Keyword(s):

Plaque Psoriasis ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17113 ◽

2021 ◽

Author(s):

M.G. Lebwohl ◽

L. Stein Gold ◽

K. Papp ◽

G. Han ◽

D.M. Pariser ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.455 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB120

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.44 ◽

2021 ◽

Vol 5 (6) ◽

pp. s44

Author(s):

Linda Stein Gold ◽

Melinda Gooderham ◽

Kim Papp ◽

Laura Ferris ◽

Mark Lebwohl ◽

...

Keyword(s):

Plaque Psoriasis ◽

Adult Patients ◽

Chronic Plaque Psoriasis ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

N/A

Download Full-text

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.09.002 ◽

2019 ◽

Vol 80 (1) ◽

pp. 282-285 ◽

Author(s):

Mark G. Lebwohl ◽

Jeffrey L. Sugarman ◽

Linda Stein Gold ◽

David M. Pariser ◽

Tina Lin ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Download Full-text

Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study

International Journal of Geriatric Psychiatry ◽

10.1002/gps.859 ◽

2003 ◽

Vol 18 (6) ◽

pp. 549-551 ◽

Author(s):

V. P. Prasher ◽

C. Adams ◽

R. Holder ◽

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Down Syndrome ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long‐Term Open‐Label Study

Neuromodulation Technology at the Neural Interface ◽

10.1111/ner.13465 ◽

2021 ◽

Author(s):

Adnan Al‐Kaisy ◽

Stefano Palmisani ◽

Roy Carganillo ◽

Samuel Wesley ◽

David Pang ◽

...

Keyword(s):

Spinal Cord ◽

Chronic Migraine ◽

Spinal Cord Stimulation ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Refractory Chronic Migraine

Download Full-text

Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.38 ◽

2020 ◽

Vol 4 (5) ◽

pp. s38

Author(s):

Mark G Lebwohl ◽

Jeffrey Sugarman ◽

David M Pariser ◽

Jerry Bagel ◽

Cynthia Trickett ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Abstract not available.

Download Full-text

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.08.019 ◽

2020 ◽

Vol 82 (2) ◽

pp. 389-397 ◽

Author(s):

Amy S. Paller ◽

Ying Hong ◽

Emily M. Becker ◽

Raul de Lucas ◽

Maria Paris ◽

...

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Download Full-text

Long-Term, Open-Label Study of the Safety and Efficacy of Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder

The Journal of Clinical Psychiatry ◽

10.4088/jcp.v66n0304 ◽

2005 ◽

Vol 66 (03) ◽

pp. 294-299 ◽

Author(s):

Lenard A. Adler ◽

Thomas J. Spencer ◽

Denái R. Milton ◽

Rodney J. Moore ◽

David Michelson

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Attention Deficit ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Hyperactivity Disorder

Download Full-text

Long-term Safety and Efficacy of Vigabatrin in Japanese Patients with Infantile Spasms: A Multicenter Open-label Study

Journal of the Japan Epilepsy Society ◽

10.3805/jjes.36.17 ◽

2018 ◽

Vol 36 (1) ◽

pp. 17-31 ◽

Author(s):

Yoko Ohtsuka ◽

Masayuki Horiguchi

Keyword(s):

Japanese Patients ◽

Infantile Spasms ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text